Acelyrin (SLRN) Stock Price, News & Analysis

Company Overview

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.

Key Stats

• Today's Range: $2.27 to $2.27
• 50-Day Range: $2.05 to $2.48
• 52-Week Range: $1.85 to $7.10
• Volume: N/A
• Average Volume: 1.29 million shs
• Market Capitalization: $229.17 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.60
• Consensus Rating: Hold

Acelyrin Stock Analysis - MarketRank™

Acelyrin scored higher than 42% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Acelyrin has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Acelyrin has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Acelyrin are expected to grow in the coming year, from ($2.53) to ($2.19) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Acelyrin is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Acelyrin is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Acelyrin has a P/B Ratio of 0.34. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for SLRN.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Acelyrin does not currently pay a dividend.

Dividend Growth

Acelyrin does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for SLRN.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added Acelyrin to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Acelyrin insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.60% of the stock of Acelyrin is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

87.31% of the stock of Acelyrin is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SLRN Stock Analysis - Frequently Asked Questions

How were Acelyrin's earnings last quarter?

Acelyrin, Inc. (NASDAQ:SLRN) issued its quarterly earnings data on Wednesday, May, 14th. The company reported ($0.55) EPS for the quarter, topping analysts' consensus estimates of ($0.95) by $0.40.

When did Acelyrin IPO?

Acelyrin (SLRN) raised $540 million in an initial public offering on Friday, May 5th 2023. The company issued 30,000,000 shares at $18.00 per share.

What other stocks do shareholders of Acelyrin own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Acelyrin investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Walmart (WMT) and Netflix (NFLX).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 8/11/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SLRN
• CIK: 1962918
• Web: www.acelyrin.com
• Phone: 805-730-0360
• Fax: N/A
• Employees: 135
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Acelyrin: $9.60
• High Price Target: $20.00
• Low Price Target: $3.00
• Potential Upside/Downside: +322.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.69)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$381.64 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -44.12%
• Return on Assets: -39.02%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.15
• Quick Ratio: 7.15

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.74 per share
• Price / Book: 0.34

Miscellaneous

• Outstanding Shares: 100,954,000
• Free Float: 86,682,000
• Market Cap: $229.17 million
• Optionable: Optionable
• Beta: 1.07